key: cord-0749508-5komhrfn
authors: Belarbi, Zakaria; Brem, Falmata Laouan; El Ouafi, Noha
title: Upper-extremity deep venous thrombosis and bilateral pulmonary embolism in a patient with COVID-19 under prophylactic anticoagulation: A case report
date: 2022-04-02
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2022.103485
sha: 189069f4daf4a921403c327e040a28698b3e50ed
doc_id: 749508
cord_uid: 5komhrfn

The COVID-19 infection induces coagulation dysfunction resulting in an increased incidence of pulmonary embolism (PE) and deep venous thrombosis (DVT), mostly in the lower extremities. While upper-extremity DVT is less frequent than lower-extremity DVT, the thrombosis of internal jugular vein or brachiocephalic (innominate) vein is an uncommon presentation. All the current studies concerning the thrombotic risk linked to hospital COVID-19 indicate that therapeutic anticoagulation does not improve the clinical prognosis in the intensive care unit. Standard prophylactic anticoagulation is therefore recommended. But again, thrombotic complications of COVID-19 infection are still frequently reported nowadays despite anticoagulation therapy, as we can see in this case report. Here we report a rare case of a 50-year-old woman with a previous history of dyslipidemia, admitted for COVID-19 related acute respiratory failure. The patient developed during hospitalization an acute bilateral PE, with upper-extremity DVT including thrombosis of the left brachiocephalic vein extended to the left internal jugular vein, while under prophylactic anticoagulation since hospital admission, leading finally to the patient's death from respiratory failure. At present, the pathophysiology of the hypercoagulable state related to COVID-19 infection is poorly understood. The significant rate of thrombosis despite preventive and therapeutic dosage anticoagulation raises the possibility of a pathophysiology unique to COVID-19. This rare case highlights the importance of thrombotic morbidity and mortality associated with the SARS-CoV-2 epidemic, and the need for further studies to better understand the physiopathology behind the thrombotic state of COVID 19 infection and establish a more efficient way to deal with these complications.

Nevertheless, just a few upper-extremity DVT cases have been previously reported, and it is rarely reported to have all these thrombotic complications despite anticoagulant therapy.

A 50-year-old woman with a previous history of dyslipidemia, presented to the emergency department for acute respiratory distress after seven days of fever, cough, asthenia, myalgia and headache. The patient had a normal psychological state, and no history of taking drugs or any other suspicious substance. She was stable hemodynamically, with increased breathing at 30 cycles per minute, oxygen saturation at 65% in room air. On physical examination, the patient appears distressed and slightly diaphoretic. Lung auscultation revealed diffuse crackles.

Arterial blood gas showed a respiratory alkalosis (pH at 7.52), partial pressure of carbon dioxide (PCO2) at 32,4mmhg, HCO03 at 26,1mmhg, with hypoxemia (partial pressure of oxygen (PO2) at 44mmhg). The SARS-CoV-2 RT-PCR performed on nasopharyngeal swabs was positive.

Laboratory findings showed elevated white blood cells (WBC) (17470 elements/mm3), elevated levels of inflammatory markers (CRP at 316mg/L, a high level of ferritin at 818ng/mL, and a high fibrinogen level at 5.9g/L), a high D-Dimer level at (10520ng/mL), and a normal renal function.

Based on these findings, the patient was hospitalized in the intensive care unit and received azithromycin 250mg per day, ceftriaxone 2g once a day, and a prophylactic dose of low molecular weight heparin (i.e. 4000 UI once day), with a good drug tolerance. We switched to the therapeutic dose of low molecular weight heparin (7000 UI twice a day).

But unfortunately, 12 days after admission the patient deceased from respiratory failure despite a marked improvement in the inflammatory assessment. Death occurred from respiratory exhaustion following the pulmonary embolism and the sequelae of the COVID-19

infection.

Upper-extremity DVT, which refers to thrombosis of the internal jugular, brachiocephalic, brachial, subclavian, and/or axillary veins, is rarely reported [5, 6] . The annual incidence is 0.4 to 1 case per 10,000 [7] . Despite anticoagulation, the incidence of venous thromboembolism (VTE) in patients with COVID-19 infection, especially PE and DVT, is interestingly increasing [8] .

However, just a few upper extremity DVT cases were reported in patients with COVID-19

infection [9, 10, 11] . Furthermore, brachiocephalic vein thrombosis is a sporadic presentation, and to the best of our knowledge, no case has been previously reported in patients infected by the SARS-CoV-2. Our COVID-19-patient developed PE and upper-extremity DVT despite being on prophylactic anticoagulation therapy. This highlights the importance of the prothrombotic state described in patients infected by the SARS-CoV-2.

The clinical signs and symptoms of upper-extremity DVT are nonspecific and may include arm swelling, pain, visible collateral veins at the shoulder girdle or jugular distention. However asymptomatic cases have been reported. Indeed, in our case, there was barely a discreet jugular distention and a vague shoulder discomfort. The diagnosis was made on CT angiography performed for PE suspicion. Besides, for upper-extremity DVT compared to lower-extremity DVT, the diagnostic algorithms using clinical pretest probability and D-dimer have not been validated. Therefore, imaging is needed [5].

Complications of upper extremity DVT include pulmonary embolism and post-thrombotic syndrome, which occur in 6% and 5% of cases, respectively [7] . Besides, there is a risk of recurrences about 9% in this patients [12] . The mortality rate is about 10% to 50% 12 months after diagnosis, and this is very high compared with patients who have lower extremity DVT [10] . Our patient also had PE on CTPA in addition to the upper extremity DVT. However, we At present, the pathophysiology of the hypercoagulable condition is poorly understood. The significant rate of thrombosis despite preventive and therapeutic dose anticoagulation raises the possibility of a pathophysiology unique to COVID-19 infection [13, 14] . One of the proposed hypotheses is the occurrence of a severely heightened inflammatory response that leads to thrombo-inflammation via mechanisms such as complement activation, cytokine storm and endotheliitis [15, 16] . It has also been hypothesized that the virus may itself trigger the coagulation cascade [17] . Current recommendations for anticoagulant therapy indicate a prophylactic dose (i.e. 4000 UI once day) in patients hospitalized in the intensive care unit, since therapeutic dose does not improve the clinical prognosis [18, 19] . Nevertheless, we can see that thromboembolic complications can occur despite anticoagulant therapy, and sometimes with vital engagement, as we can see in our patient. The aim of this rare case is to encourage investigation of the pathophysiology of the COVID-19 related coagulopathy, as we support the hypothesis of a physiopathology unique to COVID 19 infection concerning the prothrombotic state, wich could lead to the discovery of new therapeutic perspectives to counter these thromboembolic complications.

The procoagulant state during COVID 19 is developing as a prominent pathogenic event, given the fulminant increase in thrombotic complications with their consequences on morbidity and mortality in patients infected with COVID 19. Therefore, physicians should maintain high clinical suspicion in screening COVID-19 patients, and approaches to thrombotic complications should be reviewed. This rare case of COVID-19 developing an upper-extremity DVT and pulmonary embolism under prophylactic anticoagulation, highlights the need for further studies to establish a more efficient way to deal with the prothrombotic state of COVID 19 infection.

The authors declare non-conflicts of interest.

This research did not receive any specific funding.

Ethical Approval: the work has been approved by the appropriate ethical committees related to our institution. J o u r n a l P r e -p r o o f Consent statement: Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request. 

Deep Vein Thrombosis (DVT) FREE Steering Committee. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation

Deep-vein thrombosis of the upper extremities

Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19

Isolated Radial Vein Thrombosis: Upper Extremity Deep Vein Thrombosis in a Patient With COVID-19 Infection. Cureus

Upsurge of deep venous thrombosis in patients affected by COVID-19: Preliminary data and possible explanations

Internal Jugular Vein Thrombus in Coronavirus Disease (COVID-19)

RIETE Investigators. Comparisons Between Upper and Lower Extremity Deep Vein Thrombosis: A Review of the RIETE Registry

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis? Circulation

Endothelial cell infection and endotheliitis in COVID-19

Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands

ACTION Coalition COVID-19 Brazil IV Investigators. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

Please state any sources of funding for your research All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state. I didn't receive any funding for this work

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.The patient has consented for the publication of this work. The ethics committee is the deanship of the faculty of medicine mohammed 6 oujda J o u r n a l P r e -p r o o f Consent Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.Written informed consent was obtained from the patient for publication of this case report.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors. You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

Name of the registry:2. Unique Identifying number or registration ID:3. Hyperlink to your specific registration (must be publicly accessible and will be checked):

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish